A new treatment for high blood pressure, involving a shot every six months, has shown promise in helping patients who don't respond well to traditional medications. This finding comes from the Kardia-2 study, published in the journal JAMA, which tested a drug called zilebesiran on 663 patients from eight countries. The drug was used alongside common hypertension medications like amlodipine, indapamide, or olmesartan. Results showed that patients who received zilebesiran had a more significant and consistent drop in systolic blood pressure — the top number in a blood pressure reading — compared to those who only followed their regular treatment. Zilebesiran works by using a technique called RNA interference, or RNAi. This method targets a protein called angiotensinogen, which the liver produces and plays a role in regulating blood pressure. By reducing the production of this protein, the drug helps blood vessels stay open for longer, leading to a sustained drop in blood pressure. Dr. Manish Saxena, a lead researcher from Queen Mary University of London, said that the convenience of receiving an injection only twice a year could make it easier for patients to stick with their treatment plan. The study focused on patients who had high blood pressure that was not well-controlled by standard treatments. In France alone, 17 million people have hypertension, and more than 6 million are unaware they have the condition. Despite lifestyle changes and medication, about 30% of patients with high blood pressure don’t respond well to existing treatments. Also, nearly half of patients stop taking their medication within a year of being prescribed it, showing the need for better ways to help people stay on track with their treatment. Before zilebesiran can be widely used, a larger phase 3 trial is needed to see if it reduces major cardiovascular events like heart attacks or strokes. If future studies confirm these results, zilebesiran could be used as a supplement to current oral treatments for patients who are resistant to or not following their medication regimen.